Acute Coronary Syndrome Treatment Costs from the Perspective of the Supplementary Health System
- PMID: 26559980
- PMCID: PMC4632997
- DOI: 10.5935/abc.20150129
Acute Coronary Syndrome Treatment Costs from the Perspective of the Supplementary Health System
Abstract
Background: Acute coronary syndrome (ACS) is defined as a "group of clinical symptoms compatible with acute myocardial ischemia", representing the leading cause of death worldwide, with a high clinical and financial impact. In this sense, the development of economic studies assessing the costs related to the treatment of ACS should be considered.
Objective: To evaluate costs and length of hospital stay between groups of patients treated for ACS undergoing angioplasty with or without stent implantation (stent+ / stent-), coronary artery bypass surgery (CABG) and treated only clinically (Clinical) from the perspective of the Brazilian Supplementary Health System (SHS).
Methods: A retrospective analysis of medical claims of beneficiaries of health plans was performed considering hospitalization costs and length of hospital stay for management of patients undergoing different types of treatment for ACS, between Jan/2010 and Jun/2012.
Results: The average costs per patient were R$ 18,261.77, R$ 30,611.07, R$ 37,454.94 and R$ 40,883.37 in the following groups: Clinical, stent-, stent+ and CABG, respectively. The average costs per day of hospitalization were R$ 1,987.03, R$ 4,024.72, R$ 6,033.40 and R$ 2,663.82, respectively. The average results for length of stay were 9.19 days, 7.61 days, 6.19 days and 15.20 days in these same groups. The differences were significant between all groups except Clinical and stent- and between stent + and CABG groups for cost analysis.
Conclusion: Hospitalization costs of SCA are high in the Brazilian SHS, being significantly higher when interventional procedures are required.
Conflict of interest statement
Drs. Tony Piha and Paulo Miranda are employees of AstraZeneca Brazil. Vanessa Teich, Lucas Fahham, Haline Bianca Squiassi are employees of Medinsight, company that received funding from AstraZeneca to perform the analysis and preparation of the article.
Figures
Similar articles
-
Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.Hosp Pract (1995). 2012 Feb;40(1):15-23. doi: 10.3810/hp.2012.02.944. Hosp Pract (1995). 2012. PMID: 22406879
-
Costs of payment in Thai acute coronary syndrome patients.J Med Assoc Thai. 2007 Oct;90 Suppl 1:21-31. J Med Assoc Thai. 2007. PMID: 18431883
-
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).JACC Cardiovasc Interv. 2009 Dec;2(12):1199-207. doi: 10.1016/j.jcin.2009.10.009. JACC Cardiovasc Interv. 2009. PMID: 20129546 Clinical Trial.
-
Effects on length of stay and costs with same-day retransfer to the referring hospitals for patients with acute coronary syndrome after angiography and/or percutaneous coronary intervention.Eur Heart J Acute Cardiovasc Care. 2016 Aug;5(4):375-80. doi: 10.1177/2048872615593386. Epub 2015 Jul 2. Eur Heart J Acute Cardiovasc Care. 2016. PMID: 26139591
-
Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.J Cardiovasc Surg (Torino). 2012 Oct;53(5):641-50. Epub 2012 Jan 17. J Cardiovasc Surg (Torino). 2012. PMID: 22252542 Review.
Cited by
-
A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.Pharmacoeconomics. 2019 Jul;37(7):895-919. doi: 10.1007/s40273-019-00795-4. Pharmacoeconomics. 2019. PMID: 30949988
-
Factors Associated With Hospitalization Costs of Coronary Heart Disease in Township Hospitals in Rural China.Inquiry. 2019 Jan-Dec;56:46958019886958. doi: 10.1177/0046958019886958. Inquiry. 2019. PMID: 31701787 Free PMC article.
-
Primary care in supplementary health: assessment of costs in the care of older adult patients with heart diseases.Rev Bras Enferm. 2023 Jul 10;76(3):e20220486. doi: 10.1590/0034-7167-2022-0486. eCollection 2023. Rev Bras Enferm. 2023. PMID: 37436234 Free PMC article.
-
Medicinal Plants in the Treatment of Myocardial Infarction Disease: A Systematic Review.Curr Cardiol Rev. 2024;20(4):e290424229484. doi: 10.2174/011573403X278881240405044328. Curr Cardiol Rev. 2024. PMID: 38685783 Free PMC article.
-
Association of Income Level and Ischemic Heart Disease: Potential Role of Walkability.Arq Bras Cardiol. 2023 Nov;120(11):e20220844. doi: 10.36660/abc.20220844. Arq Bras Cardiol. 2023. PMID: 38055417 Free PMC article. English, Portuguese.
References
-
- Polanczyk CA, Ribeiro JP. Coronary artery disease in Brazil: contemporary management and future perspectives. Heart. 2009;95(11):870–876. - PubMed
-
- Souza e Silva NA. Saúde cardiovascular na era tecnológica. Arq Bras Cardiol. 2004;83(6):453–455. - PubMed
-
- Ministério da Saúde . Protocolo Clínico Síndromes Coronarianas Agudas. Brasília: 2011. [2013]. Disponível em: http://portal.saude.gov.br/portal/arquivos/pdf/protocolo_clinico_sindrom....
-
- Polanczyk CA, Prado K, Borges MS, Ribeiro JP. Acute myocardial infarction in the thrombolytic era: high mortality in elderly patients. Rev Assoc Med Bras. 1993;39(2):65–72. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous